Marshall Wace LLP boosted its position in shares of Bruker Co. (NASDAQ:BRKR) by 606.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,043,570 shares of the medical research company’s stock after purchasing an additional 895,860 shares during the quarter. Marshall Wace LLP’s holdings in Bruker were worth $34,907,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Bruker by 1.0% in the third quarter. Vanguard Group Inc. now owns 10,210,783 shares of the medical research company’s stock valued at $341,550,000 after acquiring an additional 101,913 shares in the last quarter. Morgan Stanley lifted its position in shares of Bruker by 686.7% in the third quarter. Morgan Stanley now owns 411,277 shares of the medical research company’s stock valued at $13,758,000 after acquiring an additional 358,995 shares in the last quarter. TIAA CREF Investment Management LLC lifted its position in shares of Bruker by 0.9% in the third quarter. TIAA CREF Investment Management LLC now owns 922,156 shares of the medical research company’s stock valued at $30,846,000 after acquiring an additional 8,528 shares in the last quarter. Teachers Advisors LLC lifted its position in shares of Bruker by 1.0% in the third quarter. Teachers Advisors LLC now owns 242,692 shares of the medical research company’s stock valued at $8,118,000 after acquiring an additional 2,452 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Bruker by 28.4% in the third quarter. AQR Capital Management LLC now owns 2,243,794 shares of the medical research company’s stock valued at $75,055,000 after acquiring an additional 496,259 shares in the last quarter. Institutional investors own 64.87% of the company’s stock.
BRKR has been the topic of several recent research reports. BidaskClub upgraded Bruker from a “hold” rating to a “buy” rating in a research report on Friday, August 24th. Morgan Stanley downgraded Bruker from an “equal weight” rating to an “underweight” rating and upped their price objective for the company from $31.00 to $32.00 in a research report on Thursday, September 20th. ValuEngine downgraded Bruker from a “buy” rating to a “hold” rating in a research report on Friday, September 21st. UBS Group initiated coverage on Bruker in a research report on Tuesday, October 9th. They issued a “sell” rating and a $30.00 price objective on the stock. They noted that the move was a valuation call. Finally, Zacks Investment Research upgraded Bruker from a “hold” rating to a “strong-buy” rating and set a $38.00 price objective on the stock in a research report on Monday, November 12th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Bruker presently has an average rating of “Hold” and an average price target of $35.13.
Bruker stock traded down $0.24 during trading on Friday, hitting $31.77. The company’s stock had a trading volume of 154,723 shares, compared to its average volume of 508,391. The firm has a market capitalization of $5.16 billion, a P/E ratio of 26.26, a PEG ratio of 2.01 and a beta of 1.39. Bruker Co. has a 1-year low of $28.13 and a 1-year high of $36.49. The company has a current ratio of 2.24, a quick ratio of 1.32 and a debt-to-equity ratio of 0.27.
Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, November 1st. The medical research company reported $0.37 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.07. The firm had revenue of $466.60 million during the quarter, compared to analyst estimates of $451.88 million. Bruker had a return on equity of 27.46% and a net margin of 5.24%. The business’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.29 earnings per share. As a group, equities analysts predict that Bruker Co. will post 1.4 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 21st. Shareholders of record on Monday, December 3rd will be paid a dividend of $0.04 per share. The ex-dividend date of this dividend is Friday, November 30th. This represents a $0.16 annualized dividend and a yield of 0.50%. Bruker’s dividend payout ratio is presently 13.22%.
TRADEMARK VIOLATION WARNING: This report was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://transcriptdaily.com/2018/12/07/bruker-co-brkr-shares-bought-by-marshall-wace-llp.html.
Bruker Company Profile
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
See Also: Cost of Capital Explained
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR).
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.